Molbio Diagnostics IPO: A High-Risk Investment with Growth Potential

Molbio Diagnostics, a leader in molecular diagnostics, is set to attract high-risk investors with its upcoming Initial Public Offering (IPO). The company aims to raise ₹200 crore through new share issuances to bolster its capital expenditure. Additionally, it plans to reduce the promoter stake by generating ₹740 crore via an offer for sale.

Financial Ambitions and Stake Adjustments

Post-IPO, the promoter group's stake will decline from 46.6% to 43%. Molbio, which operates six manufacturing facilities in India, serves clients in over 90 countries. The company's clientele includes government health programs, diagnostic laboratories, hospitals, and international healthcare organizations, with its top clients contributing over half of the revenue.

Incorporated in 2000, Molbio focuses on developing diagnostic solutions for infectious and non-communicable diseases. A significant portion of its revenue, over four-fifths, comes from government and international aid agencies. Its flagship product, the 'Truenat' platform, is a portable diagnostic system designed for resource-limited settings, offering accurate test results within an hour.

Revenue Growth and Market Position

The company boasts a robust financial performance, with its revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. Net profit also saw a substantial rise, growing 40.2% annually to ₹164.1 crore. The EBITDA grew 33.2% to ₹328.2 crore, with the EBITDA margin improving slightly to 22.6% in FY26 from 22% in FY24.

Molbio's revenue is heavily reliant on the sale of test kits, which account for 74% of its income. Notably, 70% of this comes from diagnostic test kits for Tuberculosis, highlighting the company's stronghold in this segment.

Valuation and Market Comparison

Molbio's IPO price-earnings (P/E) multiple stands at up to 57, based on its post-IPO equity and net profit for FY26. While it lacks directly comparable listed peers in India, similar companies in the healthcare diagnostics and medical device sectors, such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, trade at P/E multiples ranging from 54 to 81.

For investors with a high-risk appetite, Molbio Diagnostics presents a promising opportunity. The company's strategic initiatives and strong market presence in the diagnostics sector underscore its potential for long-term growth.